The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders

BACKGROUND: Vaccination against SARS-CoV-2 is a highly effective strategy to protect against infection, which is predominantly mediated by vaccine-induced antibodies. Postvaccination antibodies are robustly produced by those with inflammatory bowel disease (IBD) even on immune-modifying therapies bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dalin, Xu, Alexander, Mengesha, Emebet, Elyanow, Rebecca, Gittelman, Rachel M., Chapman, Heidi, Prostko, John C., Frias, Edwin C., Stewart, James L., Pozdnyakova, Valeriya, Debbas, Philip, Mujukian, Angela, Horizon, Arash A, Merin, Noah, Joung, Sandy, Botwin, Gregory J., Sobhani, Kimia, Figueiredo, Jane C., Cheng, Susan, Kaplan, Ian M., McGovern, Dermot P.B., Merchant, Akil, Melmed, Gil Y., Braun, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669852/
https://www.ncbi.nlm.nih.gov/pubmed/34909785
http://dx.doi.org/10.1101/2021.12.08.21267444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669852/
https://www.ncbi.nlm.nih.gov/pubmed/34909785
http://dx.doi.org/10.1101/2021.12.08.21267444

Ejemplares similares